drugset / Trial / NCT05047133

Effect of Early Administration of TXA in Adult Hip Fractures

NCT05047133

Phase 2/3 Recruiting 170 enrolled Ascension Health
RandomizedParallel-groupOpen-labelPrevention

Summary

This is a prospective clinical study designed to assess blood loss in intracapsular and extracapsular hip fractures undergoing operative fixation at a Level II trauma center. It is well established in the orthopedic literature that tranexamic acid (TXA) decreases blood loss and need for postoperative blood transfusion in hip fracture patients as well as total joint arthroplasty patients. A typical dosing pattern, and the dosing pattern employed at our institution, is 1 gram IV infused prior to incision followed by 1 gram IV infused at the time of wound closure.

Timeline

Start
2021-09-01
Primary completion
2022-07-01
Completion
2022-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Tranexamic Acid Small molecule 1 g Intravenous
Subject Tranexamic Acid Small molecule 2 g Intravenous

Indications

No indication recorded.